T1 Translational Research: Novel interventions for prevention and treatment of age-related conditions (R21)

Funding Agency:
National Institutes of Health

This funding opportunity announcement (FOA) encourages exploratory/developmental research projects to accelerate the pace of development of novel therapeutics involving biologics, pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical findings towards the development of new strategies for prevention and treatment of age-related pathologies.

Translational research (T2) directed towards development of health care practices, community programs and policies, including monitoring and quality improvement should refer to the parallel FOA for T2 research PAR-18-178R21 Exploratory/Developmental Grant.


  • R21 Deadlines: Feb. 16, Jun. 16, Oct. 16
  • AIDS Deadlines: Jan. 7, May 7, Sep. 7

PAR-18-177 Expiration Date September 8, 2018

Agency Website



Amount Description

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.  

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

June 16, 2018